Diagnostic Utility of Beta-Catenin in Poorly Differentiated Colorectal Carcinoma

Farukh Mir Muhammad; Farhan Akhtar; Nighat Jamal; Rabia Ahmed; Muhammad Asif; Fatima Wahan

doi:10.51253/pafmj.v73i6.6428

Authors

Farukh Mir Muhammad Department of Pathology, Pakistan Navy Ship Shifa, Karachi Pakistan
Farhan Akhtar Department of Pathology, Pak Emirates Military Hospital/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Nighat Jamal Department of Pathology, Pakistan Navy Ship Shifa, Karachi Pakistan
Rabia Ahmed Department of Pathology, Pakistan Navy Ship Shifa, Karachi Pakistan
Muhammad Asif Department of Pathology, Armed Forces Institute of Pathology/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Fatima Wahan Department of Pathology, Pakistan Navy Ship Shifa, Karachi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v73i6.6428

Keywords:

Beta-catenin, Colorectal carcinoma, Immunohistochemistry

Abstract

Objective: To determine the diagnostic ability of Beta-catenin in poorly differentiated colorectal carcinomas.

Study Design: Cross-sectional study

Place and Duration of Study: Department of Histopathology PNS Shifa Hospital, Karachi Pakistan from Jun 2019 to Jun 2020

Methodology: After ethical approval from the Institutional Review Board, 60 patients of both gender and all age group,
diagnosed with a case of colorectal carcinoma on biopsy and resection specimens analyzed on histopathology on H & E
staining at PNS SHIFA were included in the study. The resection specimens of CRC included those obtained from
hemicolectomy, abdominoperineal resection and biopsies. Beta-catenin was interpreted using immunohistochemistry as
cytoplasmic and nuclear staining with varying intensity. The scoring method was 0 as negative, 1+ as weakly positive, 2+ as
moderate positive, and 3+ as strongly positive.

Results: Among the 60 patients with resection specimens included from hemicolectomy, abdominoperineal resection and
colorectal biopsies, strong nuclear positive results were observed in 30(50 %) patients, moderate nuclear positivity in 12 (20 %), weak nuclear positivity in 6(10 %) and positive cytoplasmic staining in 12(20 %) patients.

Conclusion: Beta-catenin can be used successfully as a diagnostic utility in poorly differentiated colorectal carcinoma patients.

Downloads

Download data is not yet available.

References

Ribeiro MG, Neves LA, do Nascimento MZ, Roberto GF, MartinsAS, Tosta TA, et al. Classification of colorectal cancer based onthe association of multidimensional and multiresolution features.Expert Syst Appl 2019; 120: 262-278.http://doi.org/10.1016/j.eswa.2018.11.034.

Müller MF, Ibrahim AE, Arends MJ. Molecular pathologicalclassification of colorectal cancer. Virchows Archiv 2016; 469(2):125-134. https://doi.org/10.1007/s00428-016-1956-3.

Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L,et al. Immune and stromal classification of colorectal cancer isassociated with molecular subtypes and relevant for precisionimmunotherapy. Clin. Cancer Res 2016; 22(16): 4057-4066.https://doi.org/10.1158/1078-0432.ccr-15-2879.

Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E,Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview

and future perspectives in colorectal cancer. Int J Mol Sci 2017;18(1): 197-236. https://doi.org/10.3390%2Fijms18010197.

Zhang L, Shay JW. Multiple roles of APC and its therapeuticimplications in colorectal cancer. J Natl Cancer Inst 2017; 109(8):1-10. https://doi.org/10.1093%2Fjnci%2Fdjw332.

Dow LE, O’Rourke KP, Simon J, Tschaharganeh DF, van Es JH,Clevers H, et al. Apc restoration promotes cellular differentiationand reestablishes crypt homeostasis in colorectal cancer. Cell2015; 161(7): 1539-1552.

https://doi.org/10.1016/j.cell.2015.05.033.

Cheng X, Xu X, Chen D, Zhao F, Wang W. Therapeutic potentialof targeting the Wnt/β-catenin signaling pathway in colorectalcancer. Biomed Pharmacother 2019; 110: 473-481.https://doi.org/10.1016/j.biopha.2018.11.082.

Bahrami A, Amerizadeh F, ShahidSales S, Khazaei M,Ghayour‐Mobarhan M, Sadeghnia HR, et al. Therapeutic

potential of targeting Wnt/β‐catenin pathway in treatment ofcolorectal cancer: rational and progress. J Cell Biochem 2017;

(8): 1979-1983. https://doi.org/10.1002/jcb.25903.

Jung YS, Jun S, Lee SH, Sharma A, Park JI. Wnt2 complementsWnt/β-catenin signaling in colorectal cancer. Oncotarget. 2015;6(35): 37257-37268. https://doi.org/10.18632/oncotarget.6133.

Deitrick J, Pruitt WM. Wnt/β catenin-mediated signalingcommonly altered in colorectal cancer. Prog Mol Biol Transl Sci

; 144: 49-68. https://doi.org/10.1016/bs.pmbts.2016.09.0.

Idrees R, Fatima S, Abdul-Ghafar J, Raheem A, Ahmad Z. Cancerprevalence in Pakistan: meta-analysis of various publishedstudies to determine variation in cancer figures resulting frommarked population heterogeneity in different parts of thecountry. World J Surg Oncol 2018; 16(1): 129.https://doi.org/10.1186/s12957-018-1429-z.

Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WW. Prognostic anddiagnostic significance of β-catenin nuclear immunostaining incolorectal cancer. Clin Cancer Res 2004; 10(4): 1401-1408.https://doi.org/10.1158/1078-0432.ccr-0157-03.

Nazemalhosseini Mojarad E, Kashfi SM, Mirtalebi H, Almasi S,Chaleshi V, Farahani RK, et al. Prognostic Significance of

Nuclear β-Catenin Expression in Patients with Colorectal Cancerfrom Iran. Iran Red Crescent Med J 2015; 17(7): e22324.

https://doi.org/10.5812/ircmj.22324v2.